Global Esophageal Cancer Market – Industry Trends and Forecast to 2029

Global Esophageal Cancer Market, By Type (Esophageal Squamous-Cell Carcinoma, Esophageal Adenocarcinoma, Others), Treatment Type (Chemotherapy, Targeted Therapy, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.

Esophageal Cancer Market Analysis and Size

The esophageal cancer market is expected to witness significant growth during the forecast period. Emerging markets and huge investment in research and development are the factors responsible for the growth of this market. The growth of esophageal cancer market is enhanced by the rise in cases of esophageal cancer which creates an opportunity for the pharma companies to introduce novel therapy and promising pipeline drugs. COVID-19 also had a major impact on the market growth.

Data Bridge Market Research analyses a growth rate in the global esophageal cancer market in the forecast period 2022-2029. The expected CAGR of global esophageal cancer market is tend to be around 8.50% in the mentioned forecast period. The market was valued at USD 1.14 billion in 2021, and it would grow upto USD 2.19 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Market Definition

Esophageal cancer, known as esophageal carcinoma, originates from the tissues of the esophagus. There are various factors such as chronic consumption of the smoking and alcohol as well as Barrett esophagus diseases which can increase the chances of developing esophageal cancer. It is of great importance to the healthcare sector and thus is expected to rise high in the forecast period

Esophageal Cancer Market Scope and Segmentation

Global Esophageal Cancer Market Dynamics

Drivers

• Increase in Esophageal Cancer

It has been seen that esophageal cancer is most commonly observed in low-income countries. For instance, as per the reports of World Cancer Research Fund (WCRF) International report of 2018, highest rate of esophageal cancer was found to be in Mongolia, Malawi, Kenya, and Bangladesh. This boost the market growth.

• Rising Demand for Oral Drugs

Oral drugs is expected to boost the market growth. The segment is expected to accelerate the global esophageal cancer market as most products are available in capsule and tablet form and it is a very feasible route of administration.

Opportunities

• Increased Research Activities

Increasing R&D and launches of novel products by major players boosted the growth of the global esophageal cancer drugs market in the near future. For instance, researchers at Case Western Reserve University, U.S. in February 2019, found that by blocking two molecular pathways that send signals inside cancer cells could reduce the most common esophageal malignancy in the U.S. which is the esophageal adenocarcinoma (EAC). This, it proved that JNK/TGF-beta-targeted therapy is a new treatment approach for the treatment of esophageal cancer.

• Rising Healthcare Awareness

Health awareness amongst the population are rising which results in the prediction of drugs boost the market growth. The innovative launches in medications for the treatment of ovarian cancer are expected to prompt the market simultaneously. Different researchers are investing on launching the drugs that are beneficial for the market.This creates more opportunity in the market.

Restraints/Challenges

• Lack of Skilled Professionals

Lack of trained professionals who are unaware of the knowledge of the treatment methods for this disease could curb the growth of the global esophageal cancer market over a forecast period.

• High Cost

The huge expenditure of the treatment methods surely hamper the market growth.

This global esophageal cancer market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global esophageal cancer market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Esophageal Cancer Market Scope

The global esophageal cancer market is segmented on the basis of type, treatment type, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Esophageal Squamous-Cell Carcinoma
• Esophageal Adenocarcinoma
• Others

Treatment Type

• Chemotherapy
• Targeted Therapy
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Homecare
• Speciality Centres
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Esophageal Cancer Market Regional Analysis/Insights

The global esophageal cancer market is analysed and market size insights and trends are provided by type, treatment type, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the global ovarian cancer market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is expected to have the highest market growth due to the global leaders in research and development activities, established framework of approval process and increase in cases of esophageal cancer.

Asia-Pacific dominates the market due to the developing healthcare facilities, large number of generic manufacturer and rise in government initiatives and specialist communities.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Esophageal Cancer Market Share Analysis

The global esophageal cancer market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global esophageal cancer market.

Key players operating in the global esophageal cancer market include:

• Johnson & Johnson Private Limited (U.S.)
• Cipla Inc. (U.S.)
• Abbott (U.S.)
• AbbVie Inc. (U.S.)
• Merck KGaA (Germany)
• LEO Pharma A/S (Denmark)
• Bausch Health Companies Inc. (Canada)
• Sun Pharmaceutical Industries Ltd. (India)
• Aurobindo Pharma (India)
• Lupin (India)
• Hikma Pharmaceuticals PLC (U.K.)
• Amneal Pharmaceuticals LLC. (U.S.)
• Pfizer Inc (U.S.)
• Mylan N.V. (U.S.)
• Novartis AG (Switzerland)
• Bristol-Myers Squibb Company (U.S.)
• GSK plc. (U.K.)
• Bayer AG (Germany)
• Otsuka America Pharmaceutical, Inc (Japan)
• Jiangsu Hengrui Medicine Co., Ltd (China)